MeiraGTx Holdings Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de MeiraGTx Holdings de 7.8% y 40.5% respectivamente, mientras que el BPA crecerá en un 15.4% al año.

Información clave

7.8%

Tasa de crecimiento de los beneficios

15.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	27.1%
Tasa de crecimiento de los ingresos	40.5%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	11 Oct 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings

Oct 15

MeiraGTx: A Very Attractive Longer-Term Play, With Potential Near-Term Catalysts

Jul 15

MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are Reducing Their Forecasts For This Year

Mar 16

MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are More Bearish Than They Used To Be

Nov 16

MeiraGTx GAAP EPS of -$0.76, revenue of $10.76M

Aug 11

MeiraGTx inks $100M debt agreement backed by manufacturing facilities

Aug 03

MeiraGTx Holdings (NASDAQ:MGTX) Is In A Good Position To Deliver On Growth Plans

Apr 29

Analysts' Revenue Estimates For MeiraGTx Holdings plc (NASDAQ:MGTX) Are Surging Higher

Mar 15

MeiraGTx: Perceptive's Large Stake Makes It Interesting

Jan 19

MeiraGTx Holdings (NASDAQ:MGTX) Is In A Good Position To Deliver On Growth Plans

Dec 28

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:MGTX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	205	-92	N/A	N/A	2
12/31/2025	243	119	N/A	N/A	3
12/31/2024	32	-131	N/A	N/A	3
6/30/2024	8	-93	-105	-95	N/A
3/31/2024	11	-74	-118	-105	N/A
12/31/2023	14	-84	-126	-105	N/A
9/30/2023	7	-132	-133	-107	N/A
6/30/2023	6	-125	-135	-103	N/A
3/31/2023	14	-129	-143	-102	N/A
12/31/2022	16	-130	-118	-73	N/A
9/30/2022	42	-112	-99	-38	N/A
6/30/2022	44	-101	-97	-34	N/A
3/31/2022	39	-87	-82	-28	N/A
12/31/2021	38	-80	-57	-11	N/A
9/30/2021	20	-80	-91	-59	N/A
6/30/2021	19	-61	-77	-51	N/A
3/31/2021	16	-66	-66	-42	N/A
12/31/2020	16	-58	-87	-64	N/A
9/30/2020	19	-53	-74	-56	N/A
6/30/2020	17	-57	-79	-66	N/A
3/31/2020	17	-52	-86	-75	N/A
12/31/2019	13	-55	11	20	N/A
9/30/2019	6	-70	17	31	N/A
6/30/2019	3	-75	26	38	N/A
3/31/2019	1	-86	30	41	N/A
12/31/2018	N/A	-85	-70	-59	N/A
9/30/2018	N/A	-73	-56	-51	N/A
6/30/2018	N/A	-66	-51	-44	N/A
3/31/2018	N/A	-42	N/A	-29	N/A
12/31/2017	N/A	-32	N/A	-18	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que MGTX sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.5%).

Beneficios vs. Mercado: Se prevé que MGTX sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que MGTX sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (40.5% al año) de MGTX crezcan más rápidamente que los del mercado US (8.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (40.5% al año) de MGTX crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de MGTX se prevé que sea elevada dentro de 3 años.

MeiraGTx Holdings Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates fall by 35%

Price target increased by 40% to US$21.20

Price target decreased by 19% to US$17.50

Consensus revenue estimates decrease by 11%, EPS upgraded

Price target decreased by 10.0% to US$21.60

Forecast to breakeven in 2025

Recent updates

MeiraGTx Holdings plc Announces Positive Data from Randomized, Sham-Controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease

MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings

Consensus revenue estimates fall by 35%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

MeiraGTx Holdings plc has completed a Follow-on Equity Offering in the amount of $50 million.

Price target increased by 40% to US$21.20

Price target decreased by 19% to US$17.50

MeiraGTx: A Very Attractive Longer-Term Play, With Potential Near-Term Catalysts

MeiraGTx Holdings (NASDAQ:MGTX) Has Debt But No Earnings; Should You Worry?

Consensus revenue estimates decrease by 11%, EPS upgraded

First quarter 2024 earnings released: US$0.32 loss per share (vs US$0.62 loss in 1Q 2023)

MeiraGTx Holdings plc, Annual General Meeting, Jun 06, 2024

MeiraGTx Holdings plc Appoints Dr. Debra Yu to Serve on Each of the Compensation Committee and Science and Technology Committee of the Board

Price target decreased by 10.0% to US$21.60

New major risk - Financial position

MeiraGTx: Bota-Vec Program Advancing With Milestones Being Met

CEO, President & Director exercised options and sold US$101k worth of stock

CEO, President & Director exercised options and sold US$587k worth of stock

Forecast to breakeven in 2025

MeiraGTx Holdings plc has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

MeiraGTx Holdings plc announced that it has received $30 million in funding from Sanofi Foreign Participations B.V.

New minor risk - Share price stability

MeiraGTx Holdings plc Announces an Oral Presentation and Eight Posters At the European Society of Gene and Cell Therapy 2023 Annual Congress

Does MeiraGTx Holdings (NASDAQ:MGTX) Have A Healthy Balance Sheet?

Consensus revenue estimates decrease by 12%, EPS upgraded

New major risk - Financial position

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MeiraGTx Holdings plc Announces Positive Clinical Data from the AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

MeiraGTx Holdings plc to Present 12-Month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MeiraGTx Holdings plc announced that it expects to receive $61.525 million in funding from Perceptive Advisors LLC, 683 Capital Management, LLC, Prosight Management, LP, Adage Capital Management, L.P.

Calculating The Intrinsic Value Of MeiraGTx Holdings plc (NASDAQ:MGTX)

MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are Reducing Their Forecasts For This Year

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased by 7.4% to US$31.00

CEO, President & Director exercised options and sold US$222k worth of stock

CEO, President & Director exercised options and sold US$170k worth of stock

MeiraGTx Holdings plc cAnnounces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Consensus revenue estimates fall by 26%

MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are More Bearish Than They Used To Be

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

MeiraGTx Holdings plc announced that it has received $24.999994 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

MeiraGTx GAAP EPS of -$0.76, revenue of $10.76M

MeiraGTx Holdings plc announced that it expects to receive $100 million in funding from Perceptive Advisors LLC

MeiraGTx Holdings plc announced that it expects to receive $100 million in funding from Perceptive Advisors LLC

MeiraGTx inks $100M debt agreement backed by manufacturing facilities

MeiraGTx Holdings plc Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients Treated with Botaretigene Sparoparvovec (AAV-RPGR) Compared to Untreated Randomized Control

Consensus forecasts updated

Price target decreased to US$30.57

MeiraGTx Holdings plc Presents Clinical Data on Botaretigene Sparoparvovec for Treatment of X-Linked Retinitis Pigmentosa at Association for Research in Vision and Ophthalmology 2022 Annual Meeting

MeiraGTx Holdings plc, Annual General Meeting, Jun 07, 2022

MeiraGTx Holdings (NASDAQ:MGTX) Is In A Good Position To Deliver On Growth Plans

MeiraGTx Appoints Debra Yu to Board of Directors

Insufficient new directors

Insufficient new directors

Consensus revenue estimates increase by 28%

Analysts' Revenue Estimates For MeiraGTx Holdings plc (NASDAQ:MGTX) Are Surging Higher

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

MeiraGTx: Perceptive's Large Stake Makes It Interesting

CEO, President & Director exercised options and sold US$1.1m worth of stock

MeiraGTx Holdings (NASDAQ:MGTX) Is In A Good Position To Deliver On Growth Plans

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción